Cross‐sectional amyloid and tau PET in cognitively normal older adults enrolled in the U.S. POINTER lifestyle intervention trial
Harrison, Theresa M.; Vemuri, Prashanthi; Koeppe, Robert A.; Lockhart, Samuel N.; Jung, Youngkyoo; Borowski, Bret J.; Murphy, Alice; Ward, Tyler; Gordineer, Leslie; Woolard, Nancy; Espeland, Mark A.; Harvey, Danielle J.; Jagust, William J.; Lovato, Laura; Toga, Arthur W.; Masdeu, Joseph C.; Oh, Hwamee; Gitelman, Darren R.; Aggarwal, Neelum T.; Carrillo, Maria C.; Snyder, Heather M.; Whitmer, Rachel A.; Baker, Laura D.; DeCarli, Charles S.; Landau, Susan M.
2021-12
Citation
Harrison, Theresa M.; Vemuri, Prashanthi; Koeppe, Robert A.; Lockhart, Samuel N.; Jung, Youngkyoo; Borowski, Bret J.; Murphy, Alice; Ward, Tyler; Gordineer, Leslie; Woolard, Nancy; Espeland, Mark A.; Harvey, Danielle J.; Jagust, William J.; Lovato, Laura; Toga, Arthur W.; Masdeu, Joseph C.; Oh, Hwamee; Gitelman, Darren R.; Aggarwal, Neelum T.; Carrillo, Maria C.; Snyder, Heather M.; Whitmer, Rachel A.; Baker, Laura D.; DeCarli, Charles S.; Landau, Susan M. (2021). "Cross‐sectional amyloid and tau PET in cognitively normal older adults enrolled in the U.S. POINTER lifestyle intervention trial." Alzheimer’s & Dementia 17: n/a-n/a.
Abstract
BackgroundThe U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is a 2‐year randomized controlled trial to evaluate the effect of lifestyle interventions in older adults (60‐79 years) who are cognitively unimpaired but at increased risk for cognitive decline/dementia due to factors such as cardiovascular disease and family history. The POINTER Imaging ancillary study is collecting PET and MRI data to evaluate neuroimaging biomarkers of AD and cerebrovascular pathophysiology in this at‐risk sample.MethodPOINTER Imaging is actively enrolling 1250 participants, 23% from under‐represented racial/ethnic groups (URG), recruited from five U.S. POINTER clinical sites. Participants have undergone PET imaging with [18F]Florbetaben (FBB) to measure Aβ and [18F]MK‐6240 to measure tau burden, as well as MRI to measure brain morphometry, white matter hyperintensities and cerebral blood flow. FBB and MK‐6240 data were quality checked, pre‐processed, and quantified using previously validated methods. PET images were coregistered to a structural MRI, which was also used to create FreeSurfer‐defined reference regions and regions of interest. We examined PET imaging measures (global Aβ, regional tau) and basic demographic (age, sex, race/ethnicity) characteristics of the sample.Result96 participants (mean age 69.3±5.0) have been enrolled in POINTER Imaging. Of these, 59 (61%) are women and 22 (23%) are URG, which is similar to rates of women (75%) and URG (22%) in the main trial. This dataset is <10% of targeted enrollment, was predominantly recruited from 2/5 clinical sites and may not represent the final imaging cohort. FBB quantification (N=20) revealed a mean cortical summary SUVR of 1.09±0.12 (19.6±18.4 centiloids) (whole cerebellum normalization; previously validated positivity threshold=1.08), and 8/20 (40%) of these participants were Aβ+ (Fig. 1A). MK‐6240 quantification (N=23) showed predominantly no/minimal binding with a few exceptions in medial and lateral temporal lobes (Fig. 1B&C).ConclusionThe POINTER imaging study is meeting the target URG enrollment and representative of the main U.S. POINTER trial. Higher frequency of Aβ positivity than published in population cohorts coupled with greater cardiovascular risk factors among POINTER participants highlights our success in recruiting individuals at increased risk of cognitive decline.Publisher
Wiley Periodicals, Inc.
ISSN
1552-5260 1552-5279
Other DOIs
Types
Article
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.